For example, EGFR exon 19 deletions [38] or L858R substitutions [39] in non-small cell lung cancer, predict robust responses to first- and second-generation EGFR tyrosine kinase inhibitors [40]. Here, EGFR is linked to non-small cell lung carcinoma.